SS
NKTR icon

SBI Securities’s Nektar Therapeutics NKTR Stock Holding History

SBI Securities’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1K Sell
141
-5
-3% -$285 ﹤0.01% 1712
2025
Q4 		$6.17K Sell
146
-10
-6% -$560 ﹤0.01% 1937
2025
Q3 		$8.88K Sell
156
-4
-3% -$132 ﹤0.01% 1821
2025
Q2 		$4.13K Buy
160
+137
+596% +$1.54K ﹤0.01% 2079
2025
Q1 		$238 Buy
23
+22
+2,200% +$287 ﹤0.01% 3155
2024
Q4 		$13 Buy
+1
New +$18 ﹤0.01% 3898

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SBI Securities's NKTR Position: Q1 2026 in Review

SBI Securities reduced its Nektar Therapeutics (NKTR) stake by 3.4% in Q1 2026, selling an estimated $285 and leaving 141 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1712.

SBI Securities first reported a position in NKTR in Q4 2024 and has held it in 6 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • SBI Securities held 141 shares of Nektar Therapeutics worth $10.1K as of Q1 2026.
  • SBI Securities sold 5 Nektar Therapeutics shares in Q1 2026, an estimated $285.
  • Nektar Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #1712 holding.
  • SBI Securities first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.